GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sage Therapeutics Inc.
Sage Therapeutics is a biotech company specializing in treating brain diseases. Its stock price is a history of both breakthroughs (approval of a drug for postpartum depression) and clinical trial failures, typical in this complex field.
Share prices of companies in the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company focused on developing treatments for brain disorders, particularly depression. We've categorized it under the "Neurology" category. The chart below shows how investors value companies in the mental health sector.
Broad Market Index - GURU.Markets
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat brain disorders, particularly depression. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Sage's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
SAGE - Daily change in the company's share price Sage Therapeutics Inc.
Sage Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its depression treatments.
Daily change in the price of a set of shares in a market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of brain diseases, particularly depression. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Sage Therapeutics is a biotech company specializing in the treatment of central nervous system disorders, including depression. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sage Therapeutics Inc.
Sage Therapeutics' year-over-year performance tells the story of its performance in the CNS market. Its market cap change over the past 12 months reflects both the successful launch of its postpartum depression drug and, more importantly, the failure of its lead candidate for major depressive disorder, which was a significant blow.
Annual dynamics of market capitalization of the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in developing drugs for the treatment of brain diseases. This chart shows how its commercialization success, clinical trial results, and focus on this complex yet important area of medicine are impacting its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sage Therapeutics, a neuroscience biotech, demonstrates the challenges of commercializing drugs for brain diseases with its performance. Its performance, compared to the market, reflects the successes and failures of its innovative drugs, where investor expectations are often inflated.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sage Therapeutics Inc.
Sage is a biopharmaceutical company focused on diseases of the central nervous system. Its monthly performance reflects both sales of its approved drugs and, to a greater extent, the results of clinical trials across its extensive pipeline.
Monthly dynamics of market capitalization of the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in developing drugs to treat brain disorders such as postpartum depression and other mood disorders. The chart below shows the overall dynamics in the neuroscience sector, reflecting the growing attention to mental health issues.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working in the complex field of psychiatry can be extremely volatile. The chart below shows the overall sentiment. Is Sage Therapeutics living its own life, where the success of a new drug launch trumps any market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sage Therapeutics Inc.
Shares of Sage, a biotech company focused on brain diseases, reflect the complex treatment landscape for depression and other disorders each week. Share prices react sharply to clinical trial data and FDA decisions that could change the lives of millions of patients.
Weekly dynamics of market capitalization of the market segment - Neuro
Sage Therapeutics specializes in developing drugs to treat brain disorders, particularly depression. This chart compares its volatile, data-driven performance with general trends in neuroscience to understand how much investors believe in its scientific approach to mental health.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sage Therapeutics develops drugs to treat depression. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Sage living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
SAGE - Market capitalization of the company Sage Therapeutics Inc.
Sage's market capitalization tells the story of a biotech leader in brain health. Its volatile chart is a tale of triumph (approval of the first drug for postpartum depression) and disappointment (failure to treat primary depression). Its performance reflects the market's valuation of its remaining portfolio and scientific potential.
SAGE - Share of the company's market capitalization Sage Therapeutics Inc. within the market segment - Neuro
Sage Therapeutics is a biotech company focused on brain diseases. Its market capitalization reflects both its approved drugs and the potential for future developments. The chart shows how the market values its leadership in mental health and neuroscience.
Market capitalization of the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in diseases of the central nervous system, particularly depression. The chart below shows the market capitalization of this complex sector. Its dynamics reflect the enormous need for new treatments for mental disorders and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sage Therapeutics is a biotech company focused on brain diseases, particularly depression. Its market cap reflects the promise of new approaches to treating mental disorders. Its performance on the overall chart reflects the importance of mental health to society.
Book value capitalization of the company, segment and market as a whole
SAGE - Book value capitalization of the company Sage Therapeutics Inc.
Sage Therapeutics' foundation is its capital, which is dedicated to the development and commercialization of drugs for the treatment of central nervous system disorders, particularly postpartum depression. This is a real, scientific foundation for improving mental health. How has this innovative, yet risky, asset evolved? The chart below shows its dynamics.
SAGE - Share of the company's book capitalization Sage Therapeutics Inc. within the market segment - Neuro
Sage Therapeutics specializes in drugs for the treatment of central nervous system disorders, such as depression. The chart shows the percentage of its R&D assets, reflecting the physical foundation of its brain health research.
Market segment balance sheet capitalization - Neuro
Sage, a biopharmaceutical company focused on CNS diseases, has a moderately capital-intensive business. This requires ownership of R&D and commercial infrastructure. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Sage Therapeutics' assets aren't factories, but rather its cutting-edge scientific platform in neurosteroid chemistry for the development of drugs for depression and other brain disorders. These assets represent intellectual capital. The chart below shows how this leader in mental health compares in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sage Therapeutics Inc.
Sage Therapeutics specializes in drugs for depression and other brain disorders. Its balance sheet reflects its clinical research expenditures. Its market capitalization reflects its hopes for creating a new standard of treatment in psychiatry. The chart reflects investors' faith in its scientific approach and commercial potential.
Market to book capitalization ratio in a market segment - Neuro
Sage Therapeutics specializes in developing drugs to treat brain diseases. Its market valuation on the chart reflects both the commercial success of its unique drug for postpartum depression and the recent clinical trial failures of other candidates.
Market to book capitalization ratio for the market as a whole
Sage Therapeutics, Inc. focuses on drugs for brain diseases. Its market capitalization reflects investor expectations for breakthrough drugs. This chart shows how expectations for the biotech sector, which treats complex diseases, outpace market sentiment.
Debts of the company, segment and market as a whole
SAGE - Company debts Sage Therapeutics Inc.
Sage Therapeutics, a biotech company focused on diseases of the central nervous system, uses capital to commercialize its drugs and conduct large-scale clinical trials. This chart shows how the company is funding its breakthrough, yet expensive, research in the complex field of treating depression and other brain disorders.
Market segment debts - Neuro
Sage Therapeutics is a biotech company specializing in brain disorders, particularly postpartum depression. Commercializing a first-of-its-kind product is a costly endeavor. This chart shows how the company funds its drug launch and further research in the complex field of mental health.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sage Therapeutics Inc.
Sage Therapeutics specializes in drugs for the treatment of central nervous system disorders, particularly depression. Developing such drugs is extremely expensive. This chart shows the company's reliance on debt to finance its large-scale clinical trials, a key indicator of its financial risk.
Market segment debt to market segment book capitalization - Neuro
Sage Therapeutics specializes in developing drugs for the treatment of central nervous system disorders, with a particular focus on depression. This is one of the most complex areas in the pharmaceutical industry. The chart shows how aggressively the sector uses debt, providing context for assessing how Sage is funding its ambitious clinical programs.
Debt to book value of all companies in the market
Sage Therapeutics, Inc., focused on brain diseases, is pursuing expensive research in one of the most complex areas of medicine. This chart, reflecting the overall market debt burden, helps assess the company's financial risks. It helps understand how the company raises capital to fund its breakthrough, yet high-risk, clinical trials.
P/E of the company, segment and market as a whole
P/E - Sage Therapeutics Inc.
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat brain disorders such as depression and tremor. This chart shows how investors view its innovative approaches to neuroscience. The valuation is based on the success of clinical trials and the commercial potential of its drugs.
P/E of the market segment - Neuro
Sage Therapeutics' specialty in depression treatment is a huge but complex market. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Sage, after some drug setbacks, is valued based on its partnership with Biogen and the potential of its new approaches to treating mental disorders.
P/E of the market as a whole
Sage Therapeutics is a biopharmaceutical company specializing in developing drugs for the treatment of brain diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sage Therapeutics Inc.
This chart for Sage Therapeutics, Inc., a company focused on brain diseases, shows market expectations for sales of its depression treatments. It reflects analysts' forecasts for market acceptance of its innovative approaches to treating mental disorders.
%20P%2FE%20Sage%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sage-Therapeutics-Inc.&v=1772513781011 "Chart of the company's future (projected) P/E Sage Therapeutics Inc.")
Future (projected) P/E of the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat brain disorders, particularly postpartum depression and major depressive disorder. This chart shows industry forecasts, helping to assess how the market perceives the commercial potential of Sage's drugs in complex and large therapeutic areas.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513781037 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Sage Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs to treat brain disorders such as depression. This is a huge but complex market. The company's valuation reflects the hope for a breakthrough. This chart shows how willing investors are to invest in solving complex medical problems.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513781067 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sage Therapeutics Inc.
Sage Therapeutics specializes in developing drugs for the treatment of central nervous system disorders, with a focus on depression. The company already has commercial products. This chart illustrates the complex balance between sales revenue and the enormous research costs in one of the most complex areas of medicine.
Profit of companies in the market segment - Neuro
Sage Therapeutics specializes in developing drugs to treat brain diseases. This graph, which reflects sector profitability, demonstrates the complexity and importance of developing drugs for the central nervous system. They have achieved success in treating postpartum depression and continue research into other mental and neurological disorders.
Overall market profit
Sage Therapeutics specializes in developing drugs for the treatment of central nervous system disorders, with a particular focus on depression. This represents a huge market with unmet needs. The company's success depends on the approval and commercialization of its innovative drugs. This gross profitability chart reflects the investment climate, which is important for funding R&D in this area.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sage Therapeutics Inc.
Sage Therapeutics specializes in developing drugs for the treatment of central nervous system disorders, with a focus on depression and neurological disorders. This chart reflects analysts' forecasts for sales of currently approved drugs and the success of future developments in the complex but potentially vast mental health markets.
%20profit%20of%20the%20company%20Sage%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sage-Therapeutics-Inc.&v=1772513781165 "Graph of future (projected) profit of the company Sage Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, particularly postpartum depression. Its success depends on the commercialization of its innovative products. This biotech chart reflects the general expectations for companies working on new treatments for mental disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513781168 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Sage Therapeutics specializes in drugs for the treatment of brain diseases. The company's success depends on research results and regulatory approvals. The overall economic situation, reflected in this forecast, influences the investment climate in the biotech sector and the company's valuation.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513781169 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sage Therapeutics Inc.
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat brain disorders such as depression. The chart shows how investors estimate the revenue from its commercial product. It reflects the potential of its innovative approaches to treating central nervous system disorders.
P/S market segment - Neuro
Sage Therapeutics develops new drugs for the treatment of central nervous system disorders, with a particular focus on depression. The company's revenue depends on the commercial success of its products. This chart, which displays the average valuation in the sector, helps investors understand how the market views Sage's innovative approach to treating mood disorders.
P/S of the market as a whole
Sage Therapeutics is a biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly postpartum depression and other mood disorders. This chart, which reflects market revenue estimates, serves as a benchmark for Sage's expectations. It demonstrates the value investors place on the company's potential in the field of brain health.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sage Therapeutics Inc.
Sage Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. Its approach is based on modulating GABA receptors. This chart reflects investor expectations for the future commercial success of its drugs, which target large but complex markets.
%20P%2FS%20Sage%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sage-Therapeutics-Inc.&v=1772513781208 "The graph of the company's future (projected) P/S Sage Therapeutics Inc.")
Future (projected) P/S of the market segment - Neuro
Sage Therapeutics, Inc. is a biopharmaceutical company developing new drugs to treat central nervous system (CNS) disorders, such as postpartum depression and essential tremor. This chart shows the average estimated future sales in the neuroscience sector. It helps understand how highly the market values Sage's innovative drugs.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513781212 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, particularly depression. This chart shows investor expectations for revenue growth. Sage's success in developing new, fast-acting antidepressants could revolutionize the treatment of mental disorders.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513781229 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sage Therapeutics Inc.
This chart shows the revenue of Sage Therapeutics, a company specializing in drugs for treating brain disorders. Its revenue is generated from sales of medications, particularly those for postpartum depression. The dynamics in this chart reflect the commercial success of its innovative therapeutic approaches.
Sales of companies in the market segment - Neuro
Sage Therapeutics specializes in developing drugs for the treatment of central nervous system disorders, with a particular focus on depression and neurological disorders. This chart shows the growth of the CNS therapy market. The company's breakthrough drugs, including those for postpartum depression, are opening new markets and changing approaches to treating mental illnesses.
Overall market sales
Sage Therapeutics develops drugs to treat central nervous system disorders, such as depression. Its success depends on the approval and commercialization of its products. The overall economic situation, reflected in this chart, influences healthcare funding and the availability of innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sage Therapeutics Inc.
Sage Therapeutics specializes in developing drugs to treat brain disorders, particularly postpartum depression and other mood disorders. Future revenues depend on the commercial success of its innovative drugs. The chart shows the sales forecast for the CNS sector.
%20sales%20of%20the%20company%20Sage%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sage-Therapeutics-Inc.&v=1772513781301 "Schedule of future (projected) sales of the company Sage Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Neuro
Sage Therapeutics specializes in developing new treatments for brain diseases, with a particular focus on depression and other mood disorders. The company was a pioneer in developing drugs for postpartum depression. This chart shows the forecast for the entire neurological and psychiatric drug market, where Sage is an innovator.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513781337 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as depression. The company's success depends on the commercialization of its products. This graph, reflecting the overall state of the economy, influences healthcare budgets and pricing policies for new mental health drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513781354 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sage Therapeutics Inc.
Sage Therapeutics specializes in developing drugs to treat central nervous system disorders, particularly postpartum depression and other mood disorders. This chart shows the financial results of the company, which has brought innovative but niche products to market and continues to invest heavily in R&D to expand their use.
Market segment marginality - Neuro
Sage Therapeutics is a biopharmaceutical company focused on developing new treatments for brain disorders such as postpartum depression and essential tremor. Profitability depends on the commercial success of their approved drugs and progress in research. This chart shows the financial results of their innovative neuroscience activities.
Market marginality as a whole
Sage Therapeutics is a biopharmaceutical company focused on developing drugs to treat brain disorders, particularly postpartum depression and other mood disorders. This profitability curve is irrelevant to them. Demand for their drugs is driven by the vast unmet need for effective depression treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Sage Therapeutics Inc.
Sage Therapeutics is a biopharmaceutical company specializing in brain diseases. After receiving approval for its first drug, its staff grew significantly as it built its commercial infrastructure. This chart illustrates this transformation and the investments it made in bringing the product to market.
Share of the company's employees Sage Therapeutics Inc. within the market segment - Neuro
Sage Therapeutics is a leader in developing drugs to treat brain disorders. This chart reflects the scale of its operations. It shows the large proportion of scientists and specialists in this segment at the company, which has successfully developed and commercialized first-of-its-kind drugs for the treatment of postpartum depression.
Number of employees in the market segment - Neuro
Sage Therapeutics, Inc. is a biopharmaceutical company specializing in the development of new treatments for brain disorders, particularly in depression and neuroscience. This chart reflects employment trends in the mental health sector. The growth in the number of scientists and clinicians in this sector is driven by the development and commercialization of innovative drugs for the treatment of postpartum depression.
Number of employees in the market as a whole
Sage Therapeutics specializes in developing drugs to treat central nervous system disorders, such as depression. Demand for its products depends on the recognition and treatment of these conditions. Stable employment, as seen in this graph, ensures more people have insurance coverage for mental health treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sage Therapeutics Inc. (SAGE)
Sage Therapeutics is a biotech company specializing in drugs for the treatment of brain disorders (e.g., postpartum depression, tremor). It is an R&D company transitioning to the commercial stage. The chart shows how much the market values their unique focus on neuroscience. The high cost per employee reflects the value of their scientific platform and the potential of their drugs for the vast central nervous system market.
%20of%20the%20company%20Sage%20Therapeutics%20Inc.%20(SAGE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sage-Therapeutics-Inc.-SAGE&v=1772513781502 "Chart of market capitalization per employee (in thousands of dollars) of the company Sage Therapeutics Inc. (SAGE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in developing drugs to treat central nervous system disorders, such as depression. Its value is determined by the potential of its innovative drugs. This chart demonstrates the high market valuation of its scientific developments, based on its small team of scientists.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513781510 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Sage Therapeutics specializes in developing drugs to treat brain disorders, particularly depression. The chart illustrates their valuation in the complex field of neuroscience. It reflects how the market views their innovative approaches to treating mental disorders, where there is a significant need for new medications.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513781511 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sage Therapeutics Inc. (SAGE)
Sage Therapeutics is a biotech company specializing in brain diseases. They achieved success by bringing Zurzuvae (in partnership) to market—the first pill specifically approved for the treatment of postpartum depression. This chart shows the tradeoff: the enormous costs of R&D and the drug's launch versus the potential profits from this blockbuster.
%20Chart%20Sage%20Therapeutics%20Inc.%20(SAGE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sage-Therapeutics-Inc.-SAGE&v=1772513781512 "Company Profit Per Employee (in thousands of dollars) Chart Sage Therapeutics Inc. (SAGE)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in diseases of the central nervous system. They have commercialized drugs for the treatment of postpartum depression. This figure reflects the complex balance between sales revenue and the enormous R&D expenditures in the field of psychiatry.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513781513 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Sage Therapeutics (SAGE) is a biopharmaceutical company specializing in depression (including postpartum depression). They have approved drugs (Zulresso, Zurzuvae). This chart shows how successfully the commercial team is selling these complex (logistically and marketably) drugs to cover R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513781530 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sage Therapeutics Inc. (SAGE)
Sage Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. This chart reflects the commercial potential of its developments. Revenue growth per employee will depend on the successful sales of approved drugs and their market acceptance.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sage-Therapeutics-Inc.-SAGE&v=1772513781540 "Sales chart per company employee Sage Therapeutics Inc. (SAGE)")
Sales per employee in the market segment - Neuro
Sage Therapeutics (SAGE) is a biotech company specializing in brain health. They have approved drugs for the treatment of postpartum depression and other CNS disorders. This chart shows the revenue (from sales and partnerships) generated by each employee (scientist, commercial specialist). This measures their R&D and commercial productivity.
Sales per employee for the market as a whole
Sage Therapeutics (SAGE) is a biopharmaceutical company specializing in the treatment of depression (including postpartum depression) and other central nervous system disorders. The company has approved medications. This chart shows how successfully the company's commercial team generates revenue from sales of its niche but innovative drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Sage Therapeutics Inc. (SAGE)
Sage Therapeutics specializes in depression treatments. Its drug for postpartum depression was approved, but its drug for general depression was not. The bearish sentiment shown in this chart reflects investors' bets that the postpartum depression market is too small and the rest of the company's pipeline is weak.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sage-Therapeutics-Inc.-SAGE&v=1772513781561 "Short Shares Chart for the Company Sage Therapeutics Inc. (SAGE)")
Shares shorted by market segment - Neuro
This reflects investor skepticism about the central nervous system drug development sector. SAGE specializes in depression and neurological disorders, one of the riskiest areas of pharma. The high short interest in the sector indicates that investors expect trial failures, given the complexity of treating brain diseases.
Shares shorted by the overall market
Sage is a biotech focused on complex CNS diseases (depression, tremor). This chart shows the overall market pessimism. The company is facing challenges commercializing its drugs. When investors are fearful, they lack patience. They see their cash burn and sell off their shares, not believing in success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sage Therapeutics Inc. (SAGE)
Sage Therapeutics (SAGE) is a biotech company specializing in drugs for the treatment of depression (including postpartum depression) and other central nervous system disorders. The company's shares are binary and dependent on FDA decisions. This oscillator clearly shows "overheating" (above 70) before the decision and a collapse into "oversold" (below 30) after the rejection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sage-Therapeutics-Inc.-SAGE&v=1772513781588 "RSI 14 indicator chart for the company's stock Sage Therapeutics Inc. (SAGE)")
RSI 14 Market Segment - Neuro
Sage Therapeutics is a biopharmaceutical company specializing in brain health. They are developing new treatments for depression (including postpartum depression) and neurological disorders. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Sage (SAGE) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SAGE (Sage Therapeutics Inc.)
Sage (SAGE) is a biotech company specializing in CNS diseases, known for its breakthrough drugs for postpartum and major depression. This chart shows the average 12-month forecast. It reflects analysts' sophisticated assessment of the commercial launch of its new oral drugs and their potential in the mental health market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SAGE-Sage-Therapeutics-Inc.&v=1772513781606 "A chart showing analyst consensus forecasts for the expected stock price. SAGE (Sage Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price SAGE (Sage Therapeutics Inc.)
Sage (SAGE) is a "neuro-pioneer." It's a biotech company focused on treating depression (especially postpartum) and neurological disorders. This chart shows analysts' expectations for the stock's upside or downside. It measures the gap between the price and forecast, reflecting their view of the company's R&D portfolio after recent setbacks.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SAGE-Sage-Therapeutics-Inc.&v=1772513781619 "A chart showing the difference between the consensus forecast and the actual stock price. SAGE (Sage Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Sage Therapeutics is a biotech focused on "brain health." The company specializes in treating depression (Zulresso, Zurzuvae) and other central nervous system disorders. This chart displays analyst expectations for the *entire* neuroscience sector. It shows whether experts believe new antidepressants will be commercially successful.
Analysts' consensus forecast for the overall market share price
Sage Therapeutics (SAGE) is a neuroscience "special forces" company. They specialize in treating brain disorders, developing the first drug for postpartum depression and working on Alzheimer's disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex and risky areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sage Therapeutics Inc.
Sage is a brain-hunting biotech. Their specialty is the R&D of new drugs (neurosteroids) targeting GABA receptors for the treatment of depression (Zurzuvae) and neurological disorders. This chart is a summary of their R&D model. It reflects their (failed) commercial launch (Zurzuvae) and their (very risky) R&D pipeline.
AKIMA Market Segment Index - Neuro
Sage Therapeutics (SAGE) is a neurobiotech focused on brain health. They created the first pill specifically for postpartum depression (Zurzuvae). This chart compares their composite index to the sector, showing how their depression R&D outperforms their competitors.
The AKIM Index for the overall market
Sage Therapeutics is a biopharmaceutical company specializing in brain health. It has developed medications for postpartum depression (Zulresso, Zurzuvae). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, while overcoming commercial challenges, compares to overall trends.
